Manufacturer with High Purity and Competitive Price
Commercial Supply Rivaroxaban (CAS: 366789-02-8) Related Intermediates:
(S)-(+)-Glycidyl Phthalimide CAS: 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0
2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-1H-isoindole-1,3(2H)-dione 446292-07-5
5-Chlorothiophene-2-carboxylic acid CAS: 24065-33-6
Rivaroxaban CAS: 366789-02-8
| Chemical Name | 4-(4-Aminophenyl)morpholin-3-one |
| CAS Number | 438056-69-0 |
| CAT Number | RF-PI129 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C10H12N2O2 |
| Molecular Weight | 192.21 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Light Yellow or Light Brown Crystalline Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Melting Point | 165.0~175.0°C |
| Identification | HNMR |
| Moisture (K.F) | ≤1.0% |
| Loss on Drying | ≤0.50% |
| Residue on lgnition | ≤0.10% |
| Max Single Impurity | ≤0.50% |
| Total Impurities | ≤1.5% |
| Test Standard | Enterprise Standard |
| Usage | Rivaroxaban (CAS: 366789-02-8) Intermediate |
4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0 Synthesis Route
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-(4-Aminophenyl)morpholin-3-one (CAS: 438056-69-0) with high quality, it is an intermediate typically in the synthesis of Rivaroxaban (CAS: 366789-02-8).
Rivaroxaban (Xarelto; CAS: 366789-02-8) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban also inhibits prothrombinase activity with IC50 of 2.1 nM. Rivaroxaban also shows a similar affinity to purified human and rabbit FXa (IC50 0.7 nM and 0.8 nM, respectively), but a lesser potency against purified rat FXa (IC50 3.4 nM). Endogenous human and rabbit FXa in plasma is inhibited to a similar extent by Rivaroxaban (IC50 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 μM in vitro.
